MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations

Molecular classifications defining new tumor subtypes have been recently refined with genetic and transcriptomic analyses of benign and malignant hepatocellular tumors. Here, we performed microRNA (miRNA) profiling in two series of fully annotated liver tumors to uncover associations between oncogene/tumor suppressor mutations and clinical and pathological features. Expression levels of 250 miRNAs in 46 benign and malignant hepatocellular tumors were compared to those of 4 normal liver samples with quantitative reverse‐transcriptase polymerase chain reaction. miRNAs associated with genetic and clinical characteristics were validated in a second series of 43 liver tumor samples and 16 nontumor samples. miRNA profiling unsupervised analysis classified samples in unique clusters characterized by histological features (tumor/nontumor, P < 0.001; benign/malignant tumors, P < 0.01; inflammatory adenoma and focal nodular hyperplasia, P < 0.01), clinical characteristics [hepatitis B virus (HBV) infection, P < 0.001; alcohol consumption, P < 0.05], and oncogene/tumor suppressor gene mutations [β‐catenin, P < 0.01; hepatocyte nuclear factor 1α (HNF1α), P < 0.01]. Our study identified and validated miR‐224 overexpression in all tumors and miR‐200c, miR‐200, miR‐21, miR‐224, miR‐10b, and miR‐222 specific deregulation in benign or malignant tumors. Moreover, miR‐96 was overexpressed in HBV tumors, and miR‐126* was down‐regulated in alcohol‐related hepatocellular carcinoma. Down‐regulations of miR‐107 and miR‐375 were specifically associated with HNF1α and β‐catenin gene mutations, respectively. miR‐375 expression was highly correlated to that of β‐catenin–targeted genes as miR‐107 expression was correlated to that of HNF1α in a small interfering RNA cell line model. Thus, this strongly suggests that β‐catenin and HNF1α could regulate miR‐375 and miR‐107 expression levels, respectively. Conclusion: Hepatocellular tumors may have a distinct miRNA expression fingerprint according to malignancy, risk factors, and oncogene/tumor suppressor gene alterations. Dissecting these relationships provides a new hypothesis to understand the functional impact of miRNA deregulation in liver tumorigenesis and the promising use of miRNAs as diagnostic markers. (HEPATOLOGY 2008.)

[1]  C. Auffray,et al.  HNF1α Inactivation Promotes Lipogenesis in Human Hepatocellular Adenoma Independently of SREBP-1 and Carbohydrate-response Element-binding Protein (ChREBP) Activation* , 2007, Journal of Biological Chemistry.

[2]  T. Okanoue,et al.  Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues , 2006, Oncogene.

[3]  Cristel G. Thomas,et al.  Germline hepatocyte nuclear factor 1α and 1β mutations in renal cell carcinomas , 2005 .

[4]  H. El‐Serag,et al.  Hepatocellular carcinoma: recent trends in the United States. , 2004, Gastroenterology.

[5]  K. Ghoshal,et al.  MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.

[6]  E. Miska,et al.  How microRNAs control cell division, differentiation and death. , 2005, Current opinion in genetics & development.

[7]  Giovanni Vanni Frajese,et al.  miR-221 and miR-222 Expression Affects the Proliferation Potential of Human Prostate Carcinoma Cell Lines by Targeting p27Kip1* , 2007, Journal of Biological Chemistry.

[8]  George A Calin,et al.  Identification of differentially expressed microRNAs by microarray: A possible role for microRNA genes in pituitary adenomas , 2007, Journal of cellular physiology.

[9]  P. Sarnow,et al.  Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA , 2005, Science.

[10]  K. Ghoshal,et al.  Downregulation of miR‐122 in the rodent and human hepatocellular carcinomas , 2006, Journal of cellular biochemistry.

[11]  S. Boyault,et al.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets , 2007, Hepatology.

[12]  J. Baum,et al.  Possible association between benign hepatomas and oral contraceptives. , 1973, Lancet.

[13]  R. Weinberg,et al.  Tumour invasion and metastasis initiated by microRNA-10b in breast cancer , 2007, Nature.

[14]  Cristel G. Thomas,et al.  Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry , 2007, Hepatology.

[15]  J. Zucman‐Rossi,et al.  Genetics of hepatocellular tumors , 2006, Oncogene.

[16]  Gregory J. Hannon,et al.  microRNAs join the p53 network — another piece in the tumour-suppression puzzle , 2007, Nature Reviews Cancer.

[17]  C. Croce,et al.  MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. , 2007, Endocrine-related cancer.

[18]  Cristel G. Thomas,et al.  Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. , 2005, Human molecular genetics.

[19]  C. Croce,et al.  Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. , 2007, Cancer research.

[20]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[21]  Birgit Samans,et al.  MYCN regulates oncogenic MicroRNAs in neuroblastoma , 2007, International journal of cancer.

[22]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[23]  G. Thomas,et al.  Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. , 2001, Gastroenterology.

[24]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[25]  J. Zucman‐Rossi,et al.  Genotype–phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC , 2006, Hepatology.

[26]  I. Forgacs.  GASTROENTEROLOGY , 1988, The Lancet.

[27]  Derek Y. Chiang,et al.  Genomics and signaling pathways in hepatocellular carcinoma. , 2007, Seminars in liver disease.

[28]  C. Eng,et al.  A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. , 2006, The Journal of clinical endocrinology and metabolism.

[29]  Kimihiro Hino,et al.  Regulatory Interaction of HNF1α to microRNA194 Gene During Intestinal Epithelial Cell Differentiation , 2007 .

[30]  H. Allgayer,et al.  MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer , 2008, Oncogene.

[31]  Peter T Nelson,et al.  Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. , 2007, Molecular genetics and metabolism.

[32]  J. Zucman‐Rossi,et al.  Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. , 2008, Journal of hepatology.

[33]  A. Zucker.  CURABILITY OF BREAST CANCER , 1975, The Lancet.

[34]  Kimihiro Hino,et al.  Regulatory interaction of HNF1-alpha to microRNA-194 gene during intestinal epithelial cell differentiation. , 2007, Nucleic acids symposium series.